Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
AnTolRx logo — Innovative therapies for autoimmune diseases through targete...

AnTolRx

Innovative therapies for autoimmune diseases through targeted immune-regulation using proprietary nanoparticle-based solutions.

Founded 2015 Series A Total: $4.00M Biotechnology, Health Care

General Information

Company Name AnTolRx
Founded Year 2015
Founders / Decision Makers
Team member
Industries Biotechnology, Health Care
Funding Stage Series A
Social

BounceWatch is an independent company data service, not affiliated with AnTolRx. To contact AnTolRx, visit antolrx.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does AnTolRx compare?

A PDF of AnTolRx and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting AnTolRx soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About AnTolRx

AnTolRx is a biotechnology and healthcare startup founded in 2015, pioneering innovative therapies for autoimmune diseases. The company's slogan, "Innovative therapies for autoimmune diseases through targeted immune-regulation using proprietary nanoparticle-based solutions," encapsulates its mission. AnTolRx's approach involves developing nanoparticle-based treatments to achieve antigen-specific immune tolerance, addressing the limitations of traditional therapies that can cause severe side effects by broadly suppressing the immune system. The company's proprietary drug development technique specifically targets harmful immune cells, delivering a unique tolerogenic signal to induce an anti-inflammatory response. AnTolRx secured a significant $4.00M Series A investment on 08 September 2016 from notable investors including Orion Healthcare Equity Partners, JDRF (The Juvenile Diabetes Research Foundation), and Pfizer Venture Investments. This funding serves as a testament to the confidence these industry players have in AnTolRx's pioneering approach and potential to revolutionize autoimmune disease treatment.

Business keywords: Nanoparticle-based therapies, Autoimmune diseases, Immune regulation, Tolerogenic signal, Drug development, Antigen-specific immune tolerance, Precision medicine, Innovative therapies, Immunotherapy, Healthcare innovation

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Series A $4.00M 3
Orion Healthcare Equity Partners
Orion Healthcare Equity Partners, JDRF (The Juvenile Diabetes Research Foundation) +1
08 Sep 2016

AnTolRx Alternatives & Competitors

View All Alternatives
AnTolRx vs
ImmuneWorks
ImmuneWorks

Pioneering safe and effective treatments for autoimmune lung diseases through groundbreaking discove...

Venture round
Biotechnology, Health Care
AnTolRx vs
Apitope
Apitope Belgium

Develops drugs for treatments of allergic diseases

Series B
1 employees
Biotechnology, Health Care
AnTolRx vs
Asylia Therapeutics
Asylia Therapeutics

Innovative therapies reshaping immune responses against autoimmune, cancer, and infectious diseases.

Series A
1 employees
Biotechnology, Health Care
Also compare with: AnTolRx vs Q32 Bio Inc. Q32 Bio Inc. View all alternatives

FAQ About AnTolRx

Innovative therapies for autoimmune diseases through targeted immune-regulation using proprietary nanoparticle-based solutions.
AnTolRx was founded in 2015.
AnTolRx operates in Biotechnology and Health Care. Its work centres on Nanoparticle-based therapies, Autoimmune diseases, Immune regulation and Tolerogenic signal.
AnTolRx has completed 1 funding round, raising a total of $4.00M. The latest funding stage is Series A.
Top alternatives and competitors to AnTolRx include ImmuneWorks, Apitope, Asylia Therapeutics, Alumis, Q32 Bio Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
AnTolRx and ImmuneWorks are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for AnTolRx, https://bouncewatch.com/company/antolrx, updated 10 October 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout